Investors Should Be Aware: Pomerantz Law Firm Investigates Valneva SE Claims

Investor Alert: Pomerantz Law Firm Investigates Valneva SE

Pomerantz LLP, a leading law firm known for its expertise in corporate and securities litigation, is currently examining claims on behalf of investors in Valneva SE (NASDAQ: VALN). This investigation arises from serious concerns regarding whether the management of Valneva and certain key officers or directors have engaged in any fraudulent activities or unlawful business practices.

Background of the Investigation

On March 23, 2026, Valneva, in partnership with pharmaceutical giant Pfizer Inc., published a press release detailing the topline results from its Phase 3 clinical trial for a Lyme disease vaccine. This trial, named VALOR (NCT05477524), aimed to assess a six-valent OspA-based Lyme disease vaccine candidate. Despite the companies labeling the data as positive, the report revealed that the vaccine did not achieve its primary endpoint, largely due to a low occurrence of disease cases. This unexpected information caused significant turmoil in the market, leading to a drastic decline in Valneva's stock price—falling $3.83 per American Depositary Receipt (ADR), equivalent to a 37.11% drop, with shares closing at $6.49 on the same day.

Given these developments, investors are encouraged to reach out to Danielle Peyton at Pomerantz for more information or to discuss their potential claims. The law firm has established a dedicated line for investors to receive guidance on joining any class actions related to these claims.

About Pomerantz Law Firm

Founded over 85 years ago by the esteemed Abraham L. Pomerantz, the firm has carved out a reputation as a pioneer in the realm of securities class actions. Pomerantz has successfully recovered numerous multi-million-dollar awards for the victims of securities fraud, breaches of fiduciary duties, and corporate misconduct. They actively uphold the rights of affected investors through tireless efforts and an unwavering commitment to justice.

Currently, Pomerantz has offices across major cities including New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, further showcasing their vast reach and commitment to advocacy in corporate litigation.

What This Means for Investors

For investors in Valneva SE, this investigation highlights crucial legal questions regarding the company's operational transparency and the integrity of their public disclosures. Shareholders may want to stay vigilant as the situation develops, monitoring any updates from Pomerantz LLP regarding their findings and potential class action proceedings. Investors with losses tied to Valneva’s recent stock performance should consider seeking legal advice to understand their rights and the possible avenues for restitution.

In closing, Pomerantz LLP is not only investigating the claims but is also prepared to take necessary legal actions should they find sufficient grounds. Investors are strongly recommended to assess their positions and act timely to protect their interests in light of the ongoing investigation.

For further inquiries, investors can contact Pomerantz directly through the provided channels.

For more information, visit Pomerantz’s website.